|
Insulin is a 5.8 kDa peptide, which tends to form stable hexamers with a
molecular weight of 35 kDa. It is an important drug used to treat patients with
type I and type II diabetes. The major function of insulin in the body is to
maintain adequate blood glucose levels. Disorders associated with insulin
deficiency, left untreated, generally lead to severe hyperglycemia and
significant morbidity and mortality.
Current insulin administration involves the injection of insulin subcutaneously.
There are various forms and formulations of insulin that are tailored to control
both post-prandial and basal glucose metabolism. A significant milestone has
been achieved by TransPharma Medical in the development of transdermal systems
for the delivery of drug macromolecules, such as insulin.
TransPharma Medical's goal is to provide a non-injectable alternative to basal
insulin administration, which maintains insulin levels between meals and through
the night. TransPharma’s transdermal insulin will complement the newly emerging
rapid acting insulin products, and will provide an important treatment option
for physicians and their patients. By avoiding the need for injections and
improving control of basal glucose metabolism, TransPharma Medical’s insulin
product will provide an opportunity for insulin therapy to be used earlier in
the treatment algorithm for patients with type II diabetes, while increasing
acceptance and adherence.
TransPharma-Medical's ViaDerm™ system offers the possibility of transdermally
delivering insulin, and provides a convenient, low-cost and user-friendly
home-use, alternative to painful subcutaneous injections.
TransPharma Medical has performed a clinical, drug delivery study for measuring
transdermal delivery of insulin using the ViaDerm System in healthy adult
volunteers in comparison to 10 IU insulin injected subcutaneously.
The objectives of the study were to determine PK and PD profiles of insulin
delivered from a printed insulin patch using the ViaDerm system and to evaluate
dermal safety by assessing local erythema and edema.
Click here for the Insulin
Human Clinical Trial
|
